{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:07:11Z","timestamp":1790683631712,"version":"4.1.0"},"reference-count":145,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:00:00Z","timestamp":1669680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Natural Science Foundation of Anhui","award":["1908085MH262"],"award-info":[{"award-number":["1908085MH262"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Platinum-resistant ovarian cancer (PROC) is one of the deadliest types of epithelial ovarian cancer, and it is associated with a poor prognosis as the median overall survival (OS) is less than 12 months. Targeted therapy is a popular emerging treatment method. Several targeted therapies, including those using bevacizumab and poly (ADP-ribose) polymerase inhibitor (PARPi), have been used to treat PROC. Ataxia telangiectasia and RAD3-Related Protein Kinase inhibitors (ATRi) have attracted attention as a promising class of targeted drugs that can regulate the cell cycle and influence homologous recombination (HR) repair. In recent years, many preclinical and clinical studies have demonstrated the efficacy of ATRis in PROC. This review focuses on the anticancer mechanism of ATRis and the progress of research on ATRis for PROC.<\/jats:p>","DOI":"10.3390\/cancers14235902","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T05:45:22Z","timestamp":1669787122000},"page":"5902","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["ATR Inhibitors in Platinum-Resistant Ovarian Cancer"],"prefix":"10.3390","volume":"14","author":[{"given":"Siyu","family":"Li","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei 230031, China"},{"name":"Department of Oncology, Anhui Medical University, Hefei 230031, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei 230031, China"},{"name":"Department of Oncology, Anhui Medical University, Hefei 230031, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xichang","family":"Fei","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei 230031, China"},{"name":"Department of Oncology, Anhui Medical University, Hefei 230031, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei 230031, China"},{"name":"Department of Oncology, Anhui Medical University, Hefei 230031, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA A Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1158\/1078-0432.CCR-22-0296","article-title":"Single-Cell RNA Sequencing Reveals the Tissue Architecture in Human High-Grade Serous Ovarian Cancer","volume":"28","author":"Xu","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/jnci\/djy071","article-title":"Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage","volume":"111","author":"Peres","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"191","DOI":"10.6004\/jnccn.2021.0007","article-title":"Ovarian Cancer, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Armstrong","year":"2022","journal-title":"J. Natl. Comprehencive Cancer Netw."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ygyno.2014.02.038","article-title":"\u201cPlatinum resistant\u201d ovarian cancer: What is it, who to treat and how to measure benefit?","volume":"133","author":"Davis","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.1991.9.3.389","article-title":"Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin","volume":"9","author":"Markman","year":"1991","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/bjc.1989.132","article-title":"Response of patients in phase II studies of chemotherapy in ovarian cancer: Implications for patient treatment and the design of phase II trials","volume":"59","author":"Blackledge","year":"1989","journal-title":"Br. J. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0090-8258(90)90174-J","article-title":"Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds","volume":"36","author":"Gore","year":"1990","journal-title":"Gynecol. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2214\/AJR.09.4110","article-title":"Revised RECIST Guideline Version 1.1: What Oncologists Want to Know and What Radiologists Need to Know","volume":"195","author":"Nishino","year":"2010","journal-title":"Am. J. Roentgenol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New Guidelines to Evaluate the Response to Treatment in Solid Tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)","volume":"21","author":"Rustin","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"7533","DOI":"10.1021\/bi00347a005","article-title":"In vivo effects of cis- and trans-diamminedichloroplatinum(II) on SV40 chromosomes: Differential repair, DNA-protein crosslinking, and inhibition of replication","volume":"24","author":"Ciccarelli","year":"1985","journal-title":"Biochemistry"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/onc.2011.384","article-title":"Molecular mechanisms of cisplatin resistance","volume":"31","author":"Galluzzi","year":"2011","journal-title":"Oncogene"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial","volume":"32","author":"Hilpert","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1093\/annonc\/mdx228","article-title":"Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: Exploratory analyses of the AURELIA trial","volume":"28","author":"Bamias","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/bjc.2012.541","article-title":"Targeted anti-vascular therapies for ovarian cancer: Current evidence","volume":"108","author":"Hall","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(11)70214-5","article-title":"Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: A phase 2, multicentre, open-label, non-randomised study","volume":"12","author":"Gelmon","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1158\/1078-0432.CCR-16-2796","article-title":"A Phase I\u2013II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1\/2-Mutated Ovarian Carcinoma or Other Solid Tumors","volume":"23","author":"Kristeleit","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1055\/a-1475-4335","article-title":"Immunology and Immune Checkpoint Inhibition in Ovarian Cancer\u2014Current Aspects","volume":"81","author":"Bronger","year":"2021","journal-title":"Geburtshilfe Frauenheilkd."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ygyno.2014.05.029","article-title":"Secondary cytoreductive surgery in patients with isolated platinum-resistant recurrent ovarian cancer: A retrospective analysis","volume":"134","author":"Petrillo","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.1245\/s10434-015-4523-2","article-title":"Secondary Cytoreduction in Platinum-Resistant Recurrent Ovarian Cancer: A Single-Institution Experience","volume":"22","author":"Musella","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.semcancer.2021.02.009","article-title":"The role of surgery in platinum-resistant ovarian cancer: A call to the scientific community","volume":"77","author":"Petrillo","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e417","DOI":"10.1016\/S1470-2045(19)30401-2","article-title":"Rational combinations of immunotherapy with radiotherapy in ovarian cancer","volume":"20","author":"Herrera","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/ijo.2021.5233","article-title":"A multidisciplinary approach remains the best strategy to improve and strengthen the management of ovarian cancer (Review)","volume":"59","author":"Falzone","year":"2021","journal-title":"Int. J. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1073\/pnas.93.7.2850","article-title":"cDNA cloning and gene mapping of a candidate human cell cycle checkpoint protein","volume":"93","author":"Cimprich","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1080\/13543776.2022.2027911","article-title":"Discovery of small-molecule ATR inhibitors for potential cancer treatment: A patent review from 2014 to present","volume":"32","author":"Hu","year":"2022","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/nrc3399","article-title":"DNA repair dysregulation from cancer driver to therapeutic target","volume":"12","author":"Curtin","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Bradbury, A., Hall, S., Curtin, N., and Drew, Y. (2019). Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?. Pharmacol. Ther., 207.","DOI":"10.1016\/j.pharmthera.2019.107450"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1016\/j.jmb.2014.07.014","article-title":"Diffusion of Human Replication Protein A along Single-Stranded DNA","volume":"426","author":"Nguyen","year":"2014","journal-title":"J. Mol. Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1006\/jmbi.1996.0305","article-title":"Replication Protein A Induces the Unwinding of Long Double-stranded DNA Regions","volume":"259","author":"Treuner","year":"1996","journal-title":"J. Mol. Biol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1126\/science.1083430","article-title":"Sensing DNA Damage Through ATRIP Recognition of RPA-ssDNA Complexes","volume":"300","author":"Zou","year":"2003","journal-title":"Science"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"5586","DOI":"10.1038\/sj.onc.1207753","article-title":"Disruption of the Rad9\/Rad1\/Hus1 (9\u20131\u20131) complex leads to checkpoint signaling and replication defects","volume":"23","author":"Bao","year":"2004","journal-title":"Oncogene"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1083\/jcb.201810058","article-title":"Quantitative phosphoproteomics reveals mitotic function of the ATR activator ETAA1","volume":"218","author":"Bass","year":"2019","journal-title":"J. Cell Biol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1126\/science.aap9346","article-title":"An intrinsic S\/G 2 checkpoint enforced by ATR","volume":"361","author":"Saldivar","year":"2018","journal-title":"Science"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1126\/science.7604263","article-title":"Reversal of Raf-1 Activation by Purified and Membrane-Associated Protein Phosphatases","volume":"268","author":"Dent","year":"1995","journal-title":"Science"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1126\/science.277.5331.1501","article-title":"Mitotic and G 2 Checkpoint Control: Regulation of 14-3-3 Protein Binding by Phosphorylation of Cdc25C on Serine-216","volume":"277","author":"Peng","year":"1997","journal-title":"Science"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1535-6108(03)00048-5","article-title":"Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A","volume":"3","author":"Falck","year":"2003","journal-title":"Cancer Cell"},{"key":"ref_39","first-page":"477","article-title":"Safeguarding genome integrity: The checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication","volume":"40","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"7139","DOI":"10.1158\/0008-5472.CAN-04-1289","article-title":"ATR affecting cell radiosensitivity is dependent on homologous recombination repair but independent of nonhomologous end joining","volume":"64","author":"Wang","year":"2004","journal-title":"Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Brown, A.D., Sager, B.W., Gorthi, A., Tonapi, S.S., Brown, E.J., and Bishop, A.J.R. (2014). ATR suppresses endogenous DNA damage and allows completion of homologous recombination repair. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0091222"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1101\/gad.851000","article-title":"Functional interactions between BRCA1 and the checkpoint kinase ATR during genotoxic stress","volume":"14","author":"Tibbetts","year":"2000","journal-title":"Genes Dev."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"671","DOI":"10.15252\/embr.201541455","article-title":"ATM\/ATR -mediated phosphorylation of PALB 2 promotes RAD 51 function","volume":"17","author":"Ahlskog","year":"2016","journal-title":"EMBO Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/ncb1212","article-title":"The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair","volume":"7","author":"Sorensen","year":"2005","journal-title":"Nat. Cell Biol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1038\/onc.2008.17","article-title":"The checkpoint kinases Chk1 and Chk2 regulate the functional associations between hBRCA2 and Rad51 in response to DNA damage","volume":"27","author":"Bahassi","year":"2008","journal-title":"Oncogene"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Dibitetto, D., Sims, J.R., Ascen\u00e7\u00e3o, C.F.R., Feng, K., Kim, D., Oberly, S., Freire, R., and Smolka, M.B. (2020). Intrinsic ATR signaling shapes DNA end resection and suppresses toxic DNA-PKcs signaling. NAR Cancer, 2.","DOI":"10.1093\/narcan\/zcaa006"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Gupta, N., Huang, T.-T., Horibata, S., and Lee, J.-M. (2022). Cell cycle checkpoints and beyond: Exploiting the ATR\/CHK1\/WEE1 pathway for the treatment of PARP inhibitor\u2013resistant cancer. Pharmacol. Res., 178.","DOI":"10.1016\/j.phrs.2022.106162"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"8311","DOI":"10.1093\/nar\/gky625","article-title":"ATR-mediated proteome remodeling is a major determinant of homologous recombination capacity in cancer cells","volume":"46","author":"Kim","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"5678","DOI":"10.1093\/nar\/gkp593","article-title":"Inhibition of ATR protein kinase activity by schisandrin B in DNA damage response","volume":"37","author":"Nishida","year":"2009","journal-title":"Nucleic Acids Res."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Fokas, E., Prevo, R., Pollard, J.R., Reaper, P.M., Charlton, P.A., Cornelissen, B., Vallis, K.A., Hammond, E.M., Olcina, M.M., and Gillies McKenna, W. (2012). Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. Cell Death Dis., 3.","DOI":"10.1038\/cddis.2012.181"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.ygyno.2014.12.035","article-title":"Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells","volume":"136","author":"Teng","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nchembio.573","article-title":"Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR","volume":"7","author":"Reaper","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"5674","DOI":"10.18632\/oncotarget.2158","article-title":"Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970","volume":"5","author":"Hall","year":"2014","journal-title":"Oncotarget"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1158\/0008-5472.CAN-13-0110","article-title":"ATR Inhibition Broadly Sensitizes Ovarian Cancer Cells to Chemotherapy Independent of BRCA Status","volume":"73","author":"Huntoon","year":"2013","journal-title":"Cancer Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13048-021-00864-3","article-title":"CXCL2-mediated ATR\/CHK1 signaling pathway and platinum resistance in epithelial ovarian cancer","volume":"14","author":"Nie","year":"2021","journal-title":"J. Ovarian Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1158\/1535-7163.MCT-18-0010","article-title":"The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression","volume":"17","author":"Wallez","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1158\/1078-0432.CCR-21-1778","article-title":"ATR Inhibitors and Paclitaxel in Melanoma","volume":"27","author":"Ashworth","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_58","first-page":"1577","article-title":"ATR inhibition sensitizes liposarcoma to doxorubicin by increasing DNA damage","volume":"12","author":"Cui","year":"2022","journal-title":"Am. J. Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Sato, H., Niimi, A., Yasuhara, T., Permata, T.B.M., Hagiwara, Y., Isono, M., Nuryadi, E., Sekine, R., Oike, T., and Kakoti, S. (2017). DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. Nat. Commun., 8.","DOI":"10.1038\/s41467-017-01883-9"},{"key":"ref_60","first-page":"1307","article-title":"Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing","volume":"8","author":"Sun","year":"2018","journal-title":"Am. J. Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Patin, E.C., Dillon, M.T., Nenclares, P., Grove, L., Soliman, H., Leslie, I., Northcote, D., Bozhanova, G., Crespo-Rodriguez, E., and Baldock, H. (2022). Harnessing radiotherapy-induced NK-cell activity by combining DNA damage\u2013response inhibition and immune checkpoint blockade. J. Immunother. Cancer, 10.","DOI":"10.1136\/jitc-2021-004306"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Cheng, B., Pan, W., Xing, Y., Xiao, Y., Chen, J., and Xu, Z. (2022). Recent advances in DDR (DNA damage response) inhibitors for cancer therapy. Eur. J. Med. Chem., 230.","DOI":"10.1016\/j.ejmech.2022.114109"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.canlet.2016.09.024","article-title":"Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy","volume":"383","author":"Massey","year":"2016","journal-title":"Cancer Lett."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"392","DOI":"10.2174\/1574892813666180305165256","article-title":"PARP Inhibitors in Ovarian Cancer","volume":"13","author":"Mittica","year":"2018","journal-title":"Recent Patents Anti-Cancer Drug Discov."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Giudice, E., Gentile, M., Salutari, V., Ricci, C., Musacchio, L., Carbone, M.V., Ghizzoni, V., Camarda, F., Tronconi, F., and Nero, C. (2022). PARP Inhibitors Resistance: Mechanisms and Perspectives. Cancers, 14.","DOI":"10.3390\/cancers14061420"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1158\/1078-0432.CCR-16-2273","article-title":"Targeting the ATR\/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA-Mutant Ovarian Cancer Models","volume":"23","author":"Kim","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Kim, H., Xu, H., George, E., Hallberg, D., Kumar, S., Jagannathan, V., Medvedev, S., Kinose, Y., Devins, K., and Verma, P. (2020). Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models. Nat. Commun., 11.","DOI":"10.1038\/s41467-020-17127-2"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1200\/JCO.2009.26.9589","article-title":"Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval","volume":"28","author":"Fong","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ejmech.2019.03.034","article-title":"A comprehensive review of topoisomerase inhibitors as anticancer agents in the past decade","volume":"171","author":"Liang","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"6968","DOI":"10.1158\/0008-5472.CAN-13-3369","article-title":"ATR Inhibitors VE-821 and VX-970 Sensitize Cancer Cells to Topoisomerase I Inhibitors by Disabling DNA Replication Initiation and Fork Elongation Responses","volume":"74","author":"Martin","year":"2014","journal-title":"Cancer Res"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Hur, J., Ghosh, M., Kim, T.H., Park, N., Pandey, K., Cho, Y.B., Hong, S.D., Katuwal, N.B., Kang, M., and An, H.J. (2021). Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22031223"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11912-021-01098-8","article-title":"WEE1 Inhibitor: Clinical Development","volume":"23","author":"Kong","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"R\u00f8dland, G.E., Hauge, S., Hasvold, G., Bay, L.T.E., Raabe, T.T.H., Joel, M., and Sylju\u00e5sen, R.G. (2021). Differential Effects of Combined ATR\/WEE1 Inhibition in Cancer Cells. Cancers, 13.","DOI":"10.3390\/cancers13153790"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"4444","DOI":"10.1111\/cas.15108","article-title":"WEE1 inhibitor and ataxia telangiectasia and RAD3-related inhibitor trigger stimulator of interferon gene-dependent immune response and enhance tumor treatment efficacy through programmed death-ligand 1 blockade","volume":"112","author":"Wu","year":"2021","journal-title":"Cancer Sci."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Xu, H., George, E., Kinose, Y., Kim, H., Shah, J.B., Peake, J.D., Ferman, B., Medvedev, S., Murtha, T., and Barger, C.J. (2021). CCNE1 copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models. Cell Rep. Med., 2.","DOI":"10.1016\/j.xcrm.2021.100394"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1200\/JCO.2017.76.6915","article-title":"Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors","volume":"36","author":"Thomas","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/s41416-021-01405-x","article-title":"Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine \u00b1 cisplatin in patients with advanced solid tumours","volume":"125","author":"Middleton","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/s41416-021-01406-w","article-title":"Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours","volume":"125","author":"Shapiro","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1200\/JCO.19.02404","article-title":"Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination with Carboplatin in Patients with Advanced Solid Tumors","volume":"38","author":"Yap","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S1470-2045(20)30180-7","article-title":"Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: A multicentre, open-label, randomised, phase 2 trial","volume":"21","author":"Konstantinopoulos","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Konstantinopoulos, P., Hendrickson, A.W., Penson, R., Doyle, A., Kohn, E., Duska, L., Crispens, M., Olawaiye, A., Winer, I., and Barroilhet, L. (2019). Randomized phase II (RP2) study of ATR inhibitor M6620 in combination with gemcitabine versus gemcitabine alone in platinum-resistant high grade serous ovarian cancer (HGSOC). Ann. Oncol., 30.","DOI":"10.1093\/annonc\/mdz394.057"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.diii.2021.09.005","article-title":"Gemcitabine and nab-paclitaxel induced interstitial pneumonia","volume":"102","author":"Sabat","year":"2021","journal-title":"Diagn. Interv. Imaging"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"v431","DOI":"10.1093\/annonc\/mdz250.068","article-title":"Randomized, phase Ib\/II study of M6620 + avelumab + carboplatin vs standard care (sc) in patients (pts) with platinum-sensitive poly (ADP-ribose) polymerase inhibitor-(PARPi)-resistant ovarian cancer","volume":"30","author":"Banerjee","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1158\/1538-7445.AM2013-2348","article-title":"Abstract 2348: Discovery of AZD6738, a potent and selective inhibitor with the potential to test the clinical efficacy of ATR kinase inhibition in cancer patients","volume":"73","author":"Jones","year":"2013","journal-title":"Cancer Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1182\/blood-2021-147301","article-title":"Inhibition of ATR with AZD6738 (Ceralasertib) for the Treatment of Progressive or Relapsed Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: Safety and Preliminary Activity from a Phase Ib\/II Study","volume":"138","author":"Brunner","year":"2021","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1200\/PO.20.00439","article-title":"Ceralasertib-Mediated ATR Inhibition Combined with Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations)","volume":"5","author":"Mahdi","year":"2021","journal-title":"JCO Precis. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1158\/1078-0432.CCR-21-0251","article-title":"Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer","volume":"27","author":"Kim","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1158\/1078-0432.CCR-21-1032","article-title":"Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study","volume":"27","author":"Yap","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ygyno.2021.08.024","article-title":"Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer","volume":"163","author":"Shah","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.annonc.2021.10.009","article-title":"Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced\/metastatic melanoma who have failed prior anti-PD-1 therapy","volume":"33","author":"Kim","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Kwon, M., Kim, G., Kim, R., Kim, K.-T., Kim, S.T., Smith, S., Mortimer, P.G.S., Hong, J.Y., Loemb\u00e9, A.-B., and Irurzun-Arana, I. (2022). Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer. J. Immunother. Cancer, 10.","DOI":"10.1136\/jitc-2022-005041"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"S747","DOI":"10.1016\/j.annonc.2022.07.586","article-title":"457MO A phase I study of ATR inhibitor M1774 in patients with solid tumours (DDRiver Solid Tumours 301): Part A1 results","volume":"33","author":"Yap","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Kurz, L., Miklyaeva, A., Skowron, M.A., Overbeck, N., Poschmann, G., Becker, T., Eul, K., Kurz, T., Sch\u00f6nberger, S., and Calaminus, G. (2020). ARID1A Regulates Transcription and the Epigenetic Landscape via POLE and DMAP1 While ARID1A Deficiency or Pharmacological Inhibition Sensitizes Germ Cell Tumor Cells to ATR Inhibition. Cancers, 12.","DOI":"10.3390\/cancers12040905"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Williamson, C.T., Miller, R., Pemberton, H.N., Jones, S.E., Campbell, J., Konde, A., Badham, N., Rafiq, R., Brough, R., and Gulati, A. (2016). ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A. Nat. Commun., 7.","DOI":"10.1038\/ncomms13837"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Yuan, M., Eberhart, C.G., Pratilas, C.A., Blakeley, J.O., Davis, C., Stojanova, M., Reilly, K., Meeker, A.K., Heaphy, C.M., and Rodriguez, F.J. (2022). Therapeutic Vulnerability to ATR Inhibition in Concurrent NF1 and ATRX-Deficient\/ALT-Positive High-Grade Solid Tumors. Cancers, 14.","DOI":"10.1101\/2022.02.03.479021"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1158\/0008-5472.CAN-20-1744","article-title":"BRG1 Loss Predisposes Lung Cancers to Replicative Stress and ATR Dependency","volume":"80","author":"Gupta","year":"2020","journal-title":"Cancer Res."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Kurashima, K., Kashiwagi, H., Shimomura, I., Suzuki, A., Takeshita, F., Mazevet, M., Harata, M., Yamashita, T., Yamamoto, Y., and Kohno, T. (2020). SMARCA4 deficiency-associated heterochromatin induces intrinsic DNA replication stress and susceptibility to ATR inhibition in lung adenocarcinoma. NAR Cancer, 2.","DOI":"10.1093\/narcan\/zcaa005"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.bbagrm.2018.10.004","article-title":"Regulation of ATM and ATR by SMARCAL1 and BRG1","volume":"1861","author":"Sethy","year":"2018","journal-title":"Biochim. Biophys. Acta Gene Regul. Mech."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Schleicher, E.M., Dhoonmoon, A., Jackson, L.M., Clements, K.E., Stump, C.L., Nicolae, C.M., and Moldovan, G.-L. (2020). Dual genome-wide CRISPR knockout and CRISPR activation screens identify mechanisms that regulate the resistance to multiple ATR inhibitors. PLoS Genet., 16.","DOI":"10.1101\/2020.04.08.032854"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"112942","DOI":"10.18632\/oncotarget.22896","article-title":"Loss of NEIL3 DNA glycosylase markedly increases replication associated double strand breaks and enhances sensitivity to ATR inhibitor in glioblastoma cells","volume":"8","author":"Klattenhoff","year":"2017","journal-title":"Oncotarget"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Hustedt, N., \u00c1lvarez-Quil\u00f3n, A., McEwan, A., Yuan, J.Y., Cho, T., Koob, L., Hart, T., and Durocher, D. (2019). A consensus set of genetic vulnerabilities to ATR inhibition. Open Biol., 9.","DOI":"10.1101\/574533"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-76033-1","article-title":"The POLD1R689W variant increases the sensitivity of colorectal cancer cells to ATR and CHK1 inhibitors","volume":"10","author":"Job","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"7080","DOI":"10.18632\/oncotarget.6857","article-title":"A synthetic lethal screen identifies ATR-inhibition as a novel therapeutic approach for POLD1-deficient cancers","volume":"7","author":"Hocke","year":"2016","journal-title":"Oncotarget"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.neo.2018.08.009","article-title":"Inactivation of PRIM1 Function Sensitizes Cancer Cells to ATR and CHK1 Inhibitors","volume":"20","author":"Job","year":"2018","journal-title":"Neoplasia"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1002\/jcp.25792","article-title":"Knockdown of REV3 synergizes with ATR inhibition to promote apoptosis induced by cisplatin in lung cancer cells","volume":"232","author":"Jiang","year":"2017","journal-title":"J. Cell. Physiol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1038\/s41388-018-0606-4","article-title":"Genome-wide CRISPR screens reveal synthetic lethality of RNASEH2 deficiency and ATR inhibition","volume":"38","author":"Wang","year":"2019","journal-title":"Oncogene"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"9693","DOI":"10.1158\/0008-5472.CAN-10-2286","article-title":"Combining ATR Suppression with Oncogenic Ras Synergistically Increases Genomic Instability, Causing Synthetic Lethality or Tumorigenesis in a Dosage-Dependent Manner","volume":"70","author":"Gilad","year":"2010","journal-title":"Cancer Res"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Gralewska, P., Gajek, A., Rybaczek, D., Marczak, A., and Rogalska, A. (2022). The Influence of PARP, ATR, CHK1 Inhibitors on Premature Mitotic Entry and Genomic Instability in High-Grade Serous BRCAMUT and BRCAWT Ovarian Cancer Cells. Cells, 11.","DOI":"10.3390\/cells11121889"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1002\/1878-0261.12573","article-title":"Premature mitotic entry induced by ATR inhibition potentiates olaparib inhibition-mediated genomic instability, inflammatory signaling, and cytotoxicity in BRCA2-deficient cancer cells","volume":"13","author":"Schoonen","year":"2019","journal-title":"Mol. Oncol."},{"key":"ref_111","first-page":"7252","article-title":"Genome-wide CRISPR synthetic lethality screen identifies a role for the ADP-ribosyltransferase PARP14 in DNA replication dynamics controlled by ATR","volume":"48","author":"Dhoonmoon","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1158\/0008-5472.CAN-11-2904","article-title":"ATR\u2013ATRIP Kinase Complex Triggers Activation of the Fanconi Anemia DNA Repair Pathway","volume":"72","author":"Shigechi","year":"2012","journal-title":"Cancer Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/emboj.2009.385","article-title":"ATR activation and replication fork restart are defective in FANCM-deficient cells","volume":"29","author":"Schwab","year":"2010","journal-title":"EMBO J."},{"key":"ref_114","first-page":"1","article-title":"Radiation-dose-dependent functional synergisms between ATM, ATR and DNA-PKcs in checkpoint control and resection in G2-phase","volume":"9","author":"Mladenov","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1158\/0008-5472.CAN-13-3229","article-title":"ATR Pathway Inhibition Is Synthetically Lethal in Cancer Cells with ERCC1 Deficiency","volume":"74","author":"Mohni","year":"2014","journal-title":"Cancer Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s10549-018-4683-4","article-title":"Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapy","volume":"169","author":"Ali","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1158\/0008-5472.CAN-18-3394","article-title":"Temozolomide Sensitizes MGMT-Deficient Tumor Cells to ATR Inhibitors","volume":"79","author":"Jackson","year":"2019","journal-title":"Cancer Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.18632\/oncotarget.28090","article-title":"ATR inhibition reverses the resistance of homologous recombination deficient MGMTlow\/MMRproficient cancer cells to temozolomide","volume":"12","author":"Hose","year":"2021","journal-title":"Oncotarget"},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Ali, R., Alblihy, A., Toss, M.S., Algethami, M., Al Sunni, R., Green, A.R., Rakha, E.A., and Madhusudan, S. (2020). XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib. Ther. Adv. Med. Oncol., 12.","DOI":"10.1177\/1758835920974201"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Sultana, R., Abdel-Fatah, T., Perry, C., Moseley, P., Albarakati, N., Mohan, V., Seedhouse, C., Chan, S., and Madhusudan, S. (2013). Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Protein Kinase Inhibition Is Synthetically Lethal in XRCC1 Deficient Ovarian Cancer Cells. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0057098"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1158\/0008-5472.CAN-16-3389","article-title":"APOBEC3A and APOBEC3B Activities Render Cancer Cells Susceptible to ATR Inhibition","volume":"77","author":"Buisson","year":"2017","journal-title":"Cancer Res"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"8665","DOI":"10.1093\/nar\/gkab628","article-title":"Loss of Cyclin C or CDK8 provides ATR inhibitor resistance by suppressing transcription-associated replication stress","volume":"49","author":"Lloyd","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"King, D., Southgate, H.E.D., Roetschke, S., Gravells, P., Fields, L., Watson, J.B., Chen, L., Chapman, D., Harrison, D., and Yeomanson, D. (2021). Increased Replication Stress Determines ATR Inhibitor Sensitivity in Neuroblastoma Cells. Cancers, 13.","DOI":"10.3390\/cancers13246215"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"e1526","DOI":"10.1002\/onco.13829","article-title":"Homologous Recombination Deficiency: Cancer Predispositions and Treatment Implications","volume":"26","author":"Toh","year":"2021","journal-title":"Oncologist"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.1158\/0008-5472.CAN-20-0057","article-title":"A Genome-Wide Pooled shRNA Screen Identifies PPP2R2A as a Predictive Biomarker for the Response to ATR and CHK1 Inhibitors","volume":"80","author":"Qiu","year":"2020","journal-title":"Cancer Res."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Jo, U., Murai, Y., Chakka, S., Chen, L., Cheng, K., Murai, J., Saha, L.K., Jenkins, L.M.M., and Pommier, Y. (2021). SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR\/CHK1 inhibitors. Proc. Natl. Acad. Sci. USA, 118.","DOI":"10.1073\/pnas.2015654118"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.21037\/tlcr-21-437","article-title":"SLFN11 biomarker status predicts response to lurbinectedin as a single agent and in combination with ATR inhibition in small cell lung cancer","volume":"10","author":"Kundu","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Liu, K., Graves, J.D., Lin, F.-T., and Lin, W.-C. (2021). Overexpression of TopBP1, a canonical ATR\/Chk1 activator, paradoxically hinders ATR\/Chk1 activation in cancer. J. Biol. Chem., 296.","DOI":"10.1016\/j.jbc.2021.100382"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1101\/gad.1666208","article-title":"TopBP1 activates ATR through ATRIP and a PIKK regulatory domain","volume":"22","author":"Mordes","year":"2008","journal-title":"Genes Dev."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1172\/JCI96769","article-title":"ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D","volume":"128","author":"Komura","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_131","first-page":"1","article-title":"NUSAP1 potentiates chemoresistance in glioblastoma through its SAP domain to stabilize ATR","volume":"5","author":"Zhao","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1083\/jcb.200905006","article-title":"Tim\u2013Tipin dysfunction creates an indispensible reliance on the ATR\u2013Chk1 pathway for continued DNA synthesis","volume":"187","author":"Smith","year":"2009","journal-title":"J. Cell Biol."},{"key":"ref_133","first-page":"4344","article-title":"WWOX modulates the ATR-mediated DNA damage checkpoint response","volume":"7","author":"Hereema","year":"2015","journal-title":"Oncotarget"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejca.2016.03.005","article-title":"Homologous recombination deficiency and ovarian cancer","volume":"60","author":"Ledermann","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1146\/annurev.biochem.73.011303.073723","article-title":"Molecular Mechanisms of Mammalian DNA Repair and the DNA Damage Checkpoints","volume":"73","author":"Sancar","year":"2004","journal-title":"Annu. Rev. Biochem."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/nrc3916","article-title":"Replication stress and cancer","volume":"15","author":"Gaillard","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Bradbury, A., Zenke, F.T., Curtin, N.J., and Drew, Y. (2022). The Role of ATR Inhibitors in Ovarian Cancer: Investigating Predictive Biomarkers of Response. Cells, 11.","DOI":"10.3390\/cells11152361"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1158\/1541-7786.MCR-14-0240","article-title":"A Synthetic Lethal Screen Reveals Enhanced Sensitivity to ATR Inhibitor Treatment in Mantle Cell Lymphoma with ATM Loss-of-Function","volume":"13","author":"Menezes","year":"2015","journal-title":"Mol. Cancer Res."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1158\/1535-7163.MCT-16-0378","article-title":"AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells","volume":"16","author":"Min","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Middleton, F.K., Pollard, J.R., and Curtin, N.J. (2018). The Impact of p53 Dysfunction in ATR Inhibitor Cytotoxicity and Chemo- and Radiosensitisation. Cancers, 10.","DOI":"10.3390\/cancers10080275"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.molcel.2015.10.040","article-title":"Targeting the DNA Damage Response in Cancer","volume":"60","year":"2015","journal-title":"Mol. Cell"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1158\/1535-7163.MCT-15-0945","article-title":"ATM Mutations in Cancer: Therapeutic Implications","volume":"15","author":"Choi","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00286","article-title":"Prevalence of Homologous Recombination\u2013Related Gene Mutations Across Multiple Cancer Types","volume":"2018","author":"Heeke","year":"2018","journal-title":"JCO Precis. Oncol."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Kwok, M., Davies, N., Agathanggelou, A., Smith, E., Petermann, E., Yates, E., Brown, J., Lau, A., and Stankovic, T. (2015). Synthetic lethality in chronic lymphocytic leukaemia with DNA damage response defects by targeting the ATR pathway. Lancet, 385.","DOI":"10.1016\/S0140-6736(15)60373-7"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1158\/0008-5472.CAN-16-3398","article-title":"ATM Deficiency Is Associated with Sensitivity to PARP1- and ATR Inhibitors in Lung Adenocarcinoma","volume":"77","author":"Schmitt","year":"2017","journal-title":"Cancer Res."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/23\/5902\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:29:45Z","timestamp":1760146185000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/23\/5902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,29]]},"references-count":145,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["cancers14235902"],"URL":"https:\/\/doi.org\/10.3390\/cancers14235902","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,29]]}}}